Vanguard Group’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-922,509
| Closed | -$285K | – | 4142 |
|
|
2017
Q3 | $285K | Buy |
922,509
+148,689
| +19% | +$59.6K | ﹤0.01% | 3854 |
|
|
2017
Q2 | $319K | Buy |
773,820
+29,902
| +4% | +$9.5K | ﹤0.01% | 3815 |
|
|
2017
Q1 | $273K | Buy |
743,918
+352,784
| +90% | +$193K | ﹤0.01% | 3855 |
|
|
2016
Q4 | $349K | Buy |
391,134
+41,169
| +12% | +$36.7K | ﹤0.01% | 3801 |
|
|
2016
Q3 | $375K | Hold |
349,965
| – | – | ﹤0.01% | 3810 |
|
|
2016
Q2 | $399K | Hold |
349,965
| – | – | ﹤0.01% | 3826 |
|
|
2016
Q1 | $630K | Buy |
349,965
+4,577
| +1% | +$7.59K | ﹤0.01% | 3727 |
|
|
2015
Q4 | $753K | Buy |
345,388
+32,045
| +10% | +$44.6K | ﹤0.01% | 3711 |
|
|
2015
Q3 | $266K | Buy |
313,343
+3,630
| +1% | +$4.11K | ﹤0.01% | 3988 |
|
|
2015
Q2 | $442K | Buy |
309,713
+23,834
| +8% | +$58.4K | ﹤0.01% | 3900 |
|
|
2015
Q1 | $929K | Buy |
285,879
+21,225
| +8% | +$72.3K | ﹤0.01% | 3652 |
|
|
2014
Q4 | $841K | Buy |
264,654
+4,236
| +2% | +$21K | ﹤0.01% | 3589 |
|
|
2014
Q3 | $2.11M | Buy |
260,418
+4,996
| +2% | +$40.9K | ﹤0.01% | 3241 |
|
|
2014
Q2 | $2.67M | Sell |
255,422
-5,831
| -2% | -$49.7K | ﹤0.01% | 3130 |
|
|
2014
Q1 | $2.37M | Buy |
261,253
+38,759
| +17% | +$230K | ﹤0.01% | 3148 |
|
|
2013
Q4 | $1.06M | Buy |
+222,494
| New | +$1.04M | ﹤0.01% | 3394 |
|
Vanguard Group's BSTG Position: Q4 2017 in Review
Vanguard Group sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 922,509 shares — an estimated $285K sold.
Vanguard Group first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $2.67M in Q2 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Vanguard Group reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Vanguard Group sold 922,509 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $285K.
- Vanguard Group first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Vanguard Group's Biostage, Inc. Common Stock position peaked at $2.67M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.